Understanding how Idiopathic Pulmonary Fibrosis changes over time
Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression Trajectory
This research aims to find markers in the blood that can help predict how Idiopathic Pulmonary Fibrosis (IPF) will progress in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11111170 on NIH RePORTER |
What this research studies
Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease where the way it progresses can be very different for each person. This makes it hard to develop new treatments because it's difficult to tell if a drug is working. Our goal is to use advanced blood tests to look at thousands of proteins in patient samples. By using powerful computer analysis, we hope to find specific protein patterns that can predict how a patient's lung function might change over a year. This could help doctors better understand each patient's disease and guide future treatment choices.
Who could benefit from this research
Good fit: This research is relevant to patients diagnosed with Idiopathic Pulmonary Fibrosis, especially those whose blood samples contribute to large research cohorts.
Not a fit: Patients without Idiopathic Pulmonary Fibrosis or those not involved in providing samples for this specific research may not directly benefit from this particular study.
Why it matters
Potential benefit: If successful, this work could lead to better ways to predict how IPF will progress, helping doctors make more informed treatment decisions and speeding up the development of new medications.
How similar studies have performed: While proteomic platforms are emerging, the ability to accurately predict IPF progression trajectory remains largely elusive, making this a novel and important area of investigation.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.